De novo glomerular diseases after renal transplantation

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 8, 2014, Pages 1479-1487

  Ponticelli, Claudio ^a   Moroni, Gabriella ^b   Glassock, Richard J ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYTOTOXIC AGENT; EPITOPE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; STEROID;

ALPORT SYNDROME; ANTI GBM GLOMERULONEPHRITIS; ARTICLE; CLINICAL TRIAL (TOPIC); COLLAPSING GLOMERULOPATHY; DIABETIC NEPHROPATHY; DRUG EFFICACY; FIBRILLARY GLOMERULONEPHRITIS; FIBROSIS; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; GLUCOSE INTOLERANCE; HEMODYNAMICS; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; INFECTIOUS PROLIFERATIVE GLOMERULONEPHRITIS; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PAUCI IMMUNE GLOMERULONEPHRITIS; PODOCYTE; RECURRENT DISEASE; SYSTEMATIC REVIEW (TOPIC); THROMBOTIC THROMBOCYTOPENIC PURPURA; ADVERSE EFFECTS; ANIMAL; GLOMERULONEPHRITIS; GLOMERULUS; KIDNEY DISEASES; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; GLOMERULONEPHRITIS; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84906774021     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12571213     Document Type: Article

References (87)

1. Chailimpamontree W, Dmitrienko S, Li G, Balshaw R, Magil A, Shapiro RJ, Landsberg D, Gill J, Keown PA; Genome Canada Biomarkers in Transplantation Group: Probability, predictors, and prognosis of posttransplantation glomerulonephritis. J Am Soc Nephrol 20: 843–851, 2009
2. Golgert WA, Appel GB, Hariharan S: Recurrent glomerulonephritis after renal transplantation: An unsolved problem. Clin J Am Soc Nephrol 3: 800–807, 2008
3. Markowitz GS, Stemmer CL, Croker BP, D’Agati VD: De novo minimal change disease. Am J Kidney Dis 32: 508–513, 1998
4. Zafarmand AA, Baranowska-Daca E, Ly PD, Tsao CC, Choi YJ, Suki WN, Truong LD: De novo minimal change disease associated with reversible post-transplant nephrotic syndrome. Areport of five cases and review of literature. Clin Transplant 16: 350–361, 2002
5. Mochizuki Y, Iwata T, Nishikido M, Uramatsu T, SakaiH, Taguchi T: De novo minimal change disease after ABO-incompatible kidney transplantation. Clin Transplant 26[Suppl 24]: 81–85, 2012
6. Madhan KK, Temple-Camp CR: Late de novo minimal change disease in a renal allograft. Saudi J Kidney Dis Transpl 20: 266–269, 2009
7. McCarthy ET, Sharma M, Savin VJ: Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 2115–2121, 2010
8. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952–960, 2011
9. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P: Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113: 1390–1397, 2004
10. Mainra R, Mulay A, Bell R, Karpinski J, Hoar S, Knoll G, Robertson S, Wang D: Sirolimus use and de novo minimal change nephropathy following renal transplantation. Transplantation 80: 1816, 2005
11. Li RM, Branton MH, Tanawattanacharoen S, Falk RA, Jennette JC, Kopp JB: Molecular identification of SV40 infection in human subjects and possible association with kidney disease. J Am Soc Nephrol 13: 2320–2330, 2002
12. Waldman M, Kopp JB: Parvovirus B19 and the kidney. Clin J Am Soc Nephrol 2[Suppl 1]: S47–S56, 2007
13. Olyaei AJ, de Mattos AM, Bennett WM: Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 7: 384–389, 2001
14. Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Péraldi MN, Helal I, Noël LH, Legendre C: High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 326–333, 2007
15. Letavernier E, Bruneval P, Vandermeersch S, Perez J, Mandet C, Belair MF, Haymann JP, Legendre C, Baud L: Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 24: 630–638, 2009
16. Cosio FG, Frankel WL, Pelletier RP, Pesavento TE, Henry ML, Ferguson RM: Focal segmental glomerulosclerosis in renal allograftswith chronic nephropathy: Implications for graft survival. Am J Kidney Dis 34: 731–738, 1999
17. Gupta R, Sharma A, Mahanta PJ, Agarwal SK, Dinda AK: Focal and segmental glomerulosclerosis in renal allograft recipients: A clinico-pathologic study of 37 cases. Saudi J Kidney Dis Transpl 24: 8–14, 2013
18. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87: 233–242, 2009
19. Meehan SM, Pascual M, Williams WW, Tolkoff-Rubin N, Delmonico FL, Cosimi AB, Colvin RB: De novo collapsing glomerulopathy in renal allografts. Transplantation 65: 1192–1197, 1998
20. Gupta R, Sharma A, Agarwal SK, Dinda AK: Collapsing glomerulopathy in renal allograft biopsies: A study of nine cases. Indian J Nephrol 21: 10–13, 2011
21. Tomlinson L, Boriskin Y, McPhee I, Holwill S, Rice P: Acute cytomegalovirus infection complicated by collapsing glomerulopathy. Nephrol Dial Transplant 18: 187–189, 2003
22. Moudgil A, Shidban H, Nast CC, Bagga A, Aswad S, Graham SL, Mendez R, Jordan SC: Parvovirus B19 infection-related complications in renal transplant recipients: Treatment with intravenous immunoglobulin. Transplantation 64: 1847–1850, 1997
23. Alachkar N, Gupta G, Montgomery RA: Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med 368: 971–973, 2013
24. Swaminathan S, Lager DJ, Qian X, Stegall MD, Larson TS, Griffin MD: Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 21: 2607–2614, 2006
25. Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW III, Mundel P: Abatacept in B7-1- positive proteinuric kidney disease. N Engl J Med 369: 2416–2423, 2013
26. Aline-Fardin A, Rifle G, Martin L, Justrabo E, Bour JB, D’Athis P, Tanter Y, Mousson C: Recurent and de novo membranous glomerulopathy after kidney transplantation. Transplant Proc 41: 669–671, 2009
27. Ponticelli C, Glassock RJ: De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease? Transpl Int 25: 1205–1210, 2012
28. Monga G, Mazzucco G, Basolo B, Quaranta S, Motta M, Segoloni G, Amoroso A: Membranous glomerulonephritis (MGN) in transplanted kidneys: Morphologic investigation on 256 renal allografts. Mod Pathol 6: 249–258, 1993
29. Kearney N, Podolak J, Matsumura L, Houghton D, Troxell M: Patterns of IgG subclass deposits in membranous glomerulonephritis in renal allografts. Transplant Proc 43: 3743–3746, 2011
30. Larsen CP, Walker PD: Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy. Transplantation 95: 1259–1262, 2013
31. Truong L, Gelfand J, D’Agati V, Tomaszewski J, Appel G, Hardy M, Pirani CL: De novo membranous glomerulonephropathy in renal allografts: A report of ten cases and review of the literature. Am J Kidney Dis 14: 131–144, 1989
32. Schwarz A, Krause PH, Offermann G, Keller F: Recurrent and de novo renal disease after kidney transplantation with or without cyclosporine A. Am J Kidney Dis 17: 524–531, 1991
33. Sethi S, Fervenza FC:Membranoproliferative glomerulonephritis— a new look at an old entity. N Engl J Med 366: 1119–1131, 2012
34. Roth D, Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G, Carreno M, Esquenazi V, Miller J: De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 59: 1676–1682, 1995
35. Hammoud H, Haem J, Laurent B, Alamartine E, Diab N, Defilippis JP, Berthoux P, Berthoux F: Glomerular disease during HCV infection in renal transplantation. Nephrol Dial Transplant 11[Suppl 4]: 54–55, 1996
36. Faguer S, Kamar N, Boulestin A, Esposito L, Durand D, Blancher A, Rostaing L: Prevalence of cryoglobulinemia and autoimmunity markers in renal-transplant patients. Clin Nephrol 69: 239–243, 2008
37. Cruzado JM, Carrera M, Torras J, Grinyo´ JM: Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 1: 171–178, 2001
38. Isaac J, Herrara GA, Shihab FS: De novo fibrillary glomerulopathy in the renal allograft of a patient with systemic lupus erythematosus. Nephron 87: 365–368, 2001
39. Rao KV, Hafner GP, Crary GS, Anderson WR, Crosson JT: De novo immunotactoid glomerulopathy of the renal allograft: Possible association with cytomegalovirus infection. Am J Kidney Dis 24: 97–103, 1994
40. Moriyama T, Nitta K, Suzuki K, Honda K, Horita S, Uchida K, Yumura W, Tanabe K, Toma H, Nihei H, Yamaguchi Y: Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation. Clin Transplant 19 [Suppl 14]: 41–48, 2005
41. Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y: Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63: 2286–2294, 2003
42. Ji S, Liu M, Chen J, Yin L, Sha G, Chen H, Liu Z, Li L: The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation. Clin Transplant 18: 536–540, 2004
43. Kowalewska J, Yuan S, Sustento-Reodica N, Nicosia RF, Smith KD, Davis CL, Alpers CE: IgA nephropathy with crescents in kidney transplant recipients. Am J KidneyDis 45: 167–175, 2005
44. Moroni G, Papaccioli D, Banfi G, Tarantino A, Ponticelli C: Acute post-bacterial glomerulonephritis in renal transplant patients: Description of three cases and review of the literature. Am J Transplant 4: 132–136, 2004
45. Plumb TJ, Greenberg A, Smith SR, Butterly DW, Pham TT, Fields TA, Howell DN: Postinfectious glomerulonephritis in renal allograft recipients. Transplantation 82: 1224–1228, 2006
46. Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Kalluri R: Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A 103: 7321–7326, 2006
47. Byrne MC, Budisavljevic MN, Fan Z, Self SE, Ploth DW: Renal transplant in patients with Alport’s syndrome. Am J Kidney Dis 39: 769–775, 2002
48. Rutgers A, Meyers KE, Canziani G, Kalluri R, Lin J, Madaio MP: High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV)NC1 collagen. Kidney Int 58: 115–122, 2000
49. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG: Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N Engl J Med 348: 2543–2556, 2003
50. Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG: Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363: 343–354, 2010
51. Temme J, Kramer A, Jager KJ, Lange K, Peters F, Müller GA, Kramar R, Heaf JG, Finne P, Palsson R, Reisæter AV, Hoitsma AJ, Metcalfe W, Postorino M, Zurriaga O, Santos JP, Ravani P, Jarraya F, Verrina E, Dekker FW, Gross O: Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. Clin J Am Soc Nephrol 7: 1969–1976, 2012
52. Asif A, Toral C, Diego J, Miller J, Roth D: Denovo ANCA-associated vasculitis occurring 14 years after kidney transplantation. Am J Kidney Dis 35: E10, 2000
53. Schultz DR, Diego JM: Antineutrophil cytoplasmic antibodies (ANCA) and systemic vasculitis: Update of assays, immunopathogenesis, controversies, and report of a novel de novo ANCA-associated vasculitis after kidney transplantation. Semin Arthritis Rheum 29: 267–285, 2000
54. Tabata H, Honda K, Moriyama T, Itabashi M, Taneda S, Takei T, Tanabe K, Teraoka S, Yamaguchi Y, Oda H, Nitta K: Two cases of ANCA-associated vasculitis in post-transplant kidney: Relapse and de novo. Clin Transplant 23[Suppl 20]: 49–53, 2009
55. Bhalla V, Nast CC, Stollenwerk N, Tran S, Barba L, Kamil ES, Danovitch G, Adler SG: Recurrent and de novo diabetic nephropathy in renal allografts. Transplantation 75: 66–71, 2003
56. Fioretto P, Mauer M: Histopathology of diabetic nephropathy. Semin Nephrol 27: 195–207, 2007
57. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrøm J, Leivestad T, Egeland T, Fauchald P: Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 64: 979–983, 1997
58. Sumrani NB, Delaney V, Ding ZK, Davis R, Daskalakis P, Friedman EA, Butt KM, Hong JH: Diabetes mellitus after renal transplantation in the cyclosporine era—an analysis of risk factors. Transplantation 51: 343–347, 1991
59. van Hooff JP, Christiaans MH, van Duijnhoven EM: Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 79: 1465–1469, 2005
60. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC: Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 331: 810, 2005
61. Johnston O, Rose CL, Webster AC, Gill JS: Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J AmSoc Nephrol 19: 1411–1418, 2008
62. Peddi VR, Wiseman A, Chavin K, Slakey D: Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev (Orlando) 27: 97–107, 2013
63. Helanterä I, Ortiz F, Räisänen-Sokolowski A, Koskinen P: Impact of glucose metabolism abnormalities on histopathological changes in kidney transplant protocol biopsies. Transpl Int 23: 374–381, 2010
64. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: A consensus algorithmfor the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29: 1963–1972, 2006
65. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, Distant DA, Hong JH, Sommer BG, Friedman EA: Diabetes mellitus after renal transplantation: As deleterious as non-transplantassociated diabetes? Transplantation 65: 380–384, 1998
66. Executive Summary: Executive summary: Standards of medical care in diabetes—2009. Diabetes Care 32[Suppl 1]: S6–S12, 2009
67. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F; ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patientswith type 2 diabetes. N Engl J Med 358: 2560–2572, 2008
68. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J: Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetesmellitus. Cochrane Database Syst Rev 11: CD008143, 2013
69. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892–1903, 2013
70. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC: Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 42: 1058–1068, 2003
71. Karthikeyan V, Parasuraman R, Shah V, Vera E, Venkat KK: Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 3: 1289–1294, 2003
72. Zarifian A, Meleg-Smith S, O’donovan R, Tesi RJ, Batuman V: Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 55: 2457–2466, 1999
73. Caires RA, Marques ID, Repizo LP, Sato VA, Carmo LP, Machado DJ, de Paula FJ, Nahas WC, David-Neto E: De novo thrombotic microangiopathy after kidney transplantation: Clinical features, treatment, and long-term patient and graft survival. Transplant Proc 44: 2388–2390, 2012
74. Ponticelli C: De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin Nephrol 67: 335–340, 2007
75. Pratap B, Abraham G, Srinivas CN, Bhaskar S: Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus. Saudi J Kidney Dis Transpl 18: 609–612, 2007
76. Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E, Birembaut P, Chanard J, Rieu P: Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 5: 2441–2447, 2005
77. Satoskar AA, Pelletier R, Adams P, Nadasdy GM, Brodsky S, Pesavento T, Henry M, Nadasdy T: De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 10: 1804–1811, 2010
78. Ponticelli C, Banfi G: Thrombotic microangiopathy after kidney transplantation. Transpl Int 19: 789–794, 2006
79. Miura M, Fujita H, Suzuki A, Kubota KC, Fukasawa Y, Shimoda N, Tsuchihashi S, Tamaki T: A case of progressive thrombotic microangiopathy after ABO-incompatible renal transplantation. Clin Transplant 25[Suppl 23]: 19–22, 2011
80. Burdmann EA, Andoh TF, Yu L, Bennett WM: Cyclosporine nephrotoxicity. Semin Nephrol 23: 465–476, 2003
81. Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, Christians U, Thurman JM: Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol 24: 1849–1862, 2013
82. Keller K, Daniel C, Schöcklmann H, Endlich KH, Kerjaschki D, Johnson RJ, Hugo C: Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 21: 2724–2735, 2006
83. Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS: De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 41: 471–479, 2003
84. Mor E, Lustig S, Tovar A, Bar-Nathan N, Shharabani E, Shapira Z, Yusim A: Thrombotic microangiopathy early after kidney transplantation: Hemolytic uremic syndrome or vascular rejection? Transplant Proc 32: 686–687, 2000
85. Wilson CH, Brown AL, White SA, Goodship TH, Sheerin NS, Manas DM: Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 92: e42–e43, 2011
86. Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A: Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation— a case report. Transplant Proc 43: 2097–2101, 2011
87. Stewart ZA, Collins TE, Schlueter AJ, Raife TI, Holanda DG, Nair R, Reed AI, Thomas CP: Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 44: 3033–3036, 2012